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TunisiaA B S T R A C T
Aim: To evaluate patients’ profiles, demographics, clinical and therapeutic approaches and
strategies in patients with tuberculous lymphadenitis (TBG).
Patients and methods: A retrospective study of all TBG-confirmed cases admitted in a
tuberculosis-specific health care facility between 1 January 2009 and 16 June 2013.
Results: A total of 181 clinical files were examined. Mean age was 32 years old; the female/
male ratio was 1.78 to 1. Raw milk consumption was noted in 1/3 of patients. Most cases
involved the head and neck region (83.4%), nodes involvement, including axillary (12 cases),
and mediastinal (9 cases). Clinical symptoms were present in only 55.2%. Tuberculin skin
test (TST) was conducted with 82.6% positive responses. Diagnostics confirmation was
done with anatomical pathology in most of the patients; only 56 of them had any
microbiology analysis done. Demonstration of acid-fast bacilli in microscopy from either
fine-needle aspirates or biopsies was done in 17.5% of cases, and cultures yielded positive
results in 27%. Treatment duration was varied. Paradoxical reactions were noted in 12% and
persistent lymphadenopathy after treatment completion was noted in 10% of cases.
Conclusions: TBG remains a disease of interest. Today, its diagnosis and management is still
a problem despite its increasing worldwide incidence, and especially in this study area. Dis-
ease control should be strengthened in this country.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Tuberculosis (TB) is one of the most frequently infectious dis-
eases in the world. The World Health Organization (WHO)
considers it as a major public health problem and counted,in 2013, more than 9 million new cases and 1.3 million deaths
worldwide [1]. TB epidemiology has radically changed since
the advent of the HIV pandemic [2], which would result in
the increased incidence of extrapulmonary tuberculosis
(EPTB) at the expense of the conventional pulmonary form
Table 1 – Demographic data of patients.
Characteristics Patients, Number (%)
Average (range)











BCG Vaccination 24 (13.3%)
TB history 10 (5.5%)
Contagion TB 24 (13.3%)
HIV 0
Raw milk consumption 62 (33.3%)
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1996 to 32.6% in 2007 while demonstrating a significant
decline in the overall incidence during the same period, and
this increase is strongly associated with lymph node TB [4].
Tuberculous lymphadenitis (TBLA) is the most common
extrapulmonary manifestation of TB. Its proportion varies
between 1.5% and 35% by country [5–7]. In Tunisia, the rate
is estimated at 23%, and thus is the second most common
form after pulmonary tuberculosis (PTB) [4].
Despite a renewed interest and a resurgence of cases in
recent years, TBLA remains a disease whose many factors
are largely unknown [7]. The diagnostic management remains
difficult [6–11]. The treatment of TBLA is based on an essen-
tially medical approach and rarely surgical excision biopsy
of affected sites with a large range of technical, protocols
and duration of treatment [11–13]. In Tunisia, there is little
information on the diagnosis and therapy of TBLA. To better
understand this disease, this study was performed to evalu-
ate patients’ profiles, demographics, clinical and therapeutic
approaches, and strategies in patients with TBLA in a popula-
tion with low prevalence for HIV infection.
Patients and methods
This is a descriptive retrospective single-center study of all
cases of TBLA admitted to the TB clinic (TBC) in Sfax between
1 January 2009 and 16 June 2013. The TBC is a center specializ-
ing in the treatment of TB which receives all tuberculous
patients diagnosed in the hospital and private structures in
the region of Sfax for additional support and monitoring of
TB. The diagnosis of TBLA stood on microbiological, anato-
mopathological, radio-clinical and/or therapeutic criteria.
Besides an unconfirmed diagnosis or incomplete files, no other
exclusions criteria were retained. The data were collected
through a form provided for this purpose. Additional data were
collected from the records of patients who were admitted in
the university hospitals of Sfax. Epi InfoTM Version 7.1.2 was
used for the acquisition and analysis of data.
Results
Epidemiology
A total of 203 cases of TBLA were identified during the study
period, of which 18 were excluded for missing data and 4
unconfirmed diagnosis of TBLA. So, the total number of con-
sidered cases is 181. The mean (±SD) age was 32 ± 18.6 years,
with a range from 3 months to 81 years. The age group ‘‘20–
30 years’’ was the most affected (33%) [1]. The female/male
ratio was 1.78:1. The majority of patients resided in the urban
area of Sfax city (60.8%). The epidemiological characteristics
of this group are summarized in Table 1.
Only 10 patients (5.5%) had a past medical history of TB,
including 5 with at least one previous episode of TBLA. No
patient was HIV positive. Diabetes mellitus was documented
only in one patient, and raw milk consumption was found
in 33.3% of cases. Two patients had congenital immunodefi-
ciency: one case with IL12 receptor deficiency and one case
with chronic granulomatous disease; both patients were aged
less than 5 years at the moment of diagnosis, and it waspresumed that BCG vaccination was the main etiology behind
both cases.
Clinical symptoms
One hundred patients (55.2%) had enlarged lymphadenopathy
(ADP). The majority of ADP cases were cervical (83.4%), and
unilateral (78.4%), sizing between 1 and 3 cm (54.6%)
(Table 2). Patients with multiple ADP all expressed at least
one sign of TB impregnation. ADPs were discharging in
18.2% of cases and firm in 23.7% of cases. About 1/3 of this
population (32.1%) presented significant weight loss. The pro-
longed daytime fever (>38 C) was reported in 21% of cases.
Asthenia and night sweats were reported in 12.1% and
11.6% of cases, respectively. Acute intra or perinodular ADP
was noted in 13 cases (7.2%), chronic cough was found in
the history of 5 patients, of whom only 1 had hemoptysis
(due to PTB). Ten cases of active PTB were found; the diagno-
sis was established in parallel while investigating for LNT.
Concomitant EPTB was found in 13 patients (miliary TB = 5;
pleural TB = 2, abdominal TB = 1, skin TB = 1, other = 4).
Tuberculosis skin Test (TST) was positive in 82.6% of these
patients (>10 mm).
Imagery
Of a total of 111 X-ray chest scans, 24.3% showed bronchial
syndrome. An ultrasound scan, predominantly cervical
(86.9%) and abdominal (4.2%), was performed at least once
on 46 of these patients (25.4%). A positive imagery concurring
with TBLA was noted in 35 patients (76%). The majority of
positive results were based on a hypoechoic image with a
hyperechoic center for lymph node abscess or necrosis,
heterogeneous hypoechoic image to newly contaminated
nodes, and calcification of one or more nodes in 7 cases
(20%; n = 35). CT scan was positive in 13 out of 20 conducted
cases.
Table 2 – Patient’s symptoms, signs and extent of lymph
nodes.
Symptom Number (%)
Weight loss 58 (32.1%)
Fever 38 (21%)
Asthenia 22 (12.1%)
Night sweats 21 (11.6%)









Not specified 6 (5%)
Lymph nodes (number, size and bilaterality)
Large (>3 cm) 62 (34.8%)
<1 cm 24 (13.3%)
Large + <1 cm 5 (2.7%)
1–3 cm 99 (54.6%)
Number of lymph nodes > 3 64 (35.4%)
Bilaterality 24 (13.3%)
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One hundred seventy-four patients (96.1%) had a
pathological-based exam. The excision biopsy was the sam-
pling means in 72% of cases, fine needle aspiration (FNA)
technique was used in 10% of cases, and 18% had both meth-
ods. The sensitivity of pathological examination was 94.2%
and 62.5%, respectively, for biopsies and FNA. Histological
analysis revealed the presence of epithelioid granulomas with
or without caseous necrosis in 95.2% of cases and giant
Langerhans cells in 64.9% of cases. Of the 4 patients excluded
from the study to be proven non-TBLA, 3 underwent histolog-
ical examination and only 1 had a suggestive result of TBLA.
The specificity of these tests would go up to 99.4%.
The mycobacterial research involved only 56 patients: 36
biopsies, 21 FNA samples and 2 fresh discharges directly from
the fistula. Ziehl Neelsen stains of biopsy were positive in 5/36
(13.9%), and 5/21 for the FNA (23.8%). Culture concerned only
35 samples (of which 11 were FNA). Culture media included
Lowenstein Jensen (LJ) for every sample and MGIT for only
14 samples. The positivity rate on LJ medium was 22.9%,
against 14.9% in MGIT (Table 3). Five bacterial strains have
been identified: 3 Mycobacterium bovis, 1 M. bovis BCG and 1Table 3 – Microbiological results according to the technique
of lymph node sampling.
FNA n/n* (%) Excision n/n* (%)
AFB smear 5/21 (23.8%) 5/36 (13.8%)
Culture on LJ. 3/11 (27%) 7/26 (26.9%)
Culture on MGIT 2/14 (14.9%)
FNA, fine needle aspiration; LJ, Lowenstein Jensen; MGIT,
mycobacteria growth indicator tube.Mycobacterium tuberculosis. These strains showed no resis-
tance to the first-line antitubercular drugs (isoniazid, rifampi-
cin, ethambutol and streptomycin). No polymerase chain
reaction (PCR) or otherwise genomic identification was per-
formed in this series.
Treatment and evolution
The majority of these patients (79%) were treated according to
the latest recommendation of the WHO: classic regimen
based on a quadruple therapy (isoniazid + rifampicin +
ethambutol + pyrazinamide) for 2 months followed by dual
therapy (isoniazid + rifampicin) for a period of 4–30 months;
60% received treatment in combined single pharmaceutical
form. The mean duration of treatment was 8.7 month-
s ± 4 months. Treatment duration stretched from 2 to
32 months. Eleven cases of drug-induced liver toxicity (cytol-
ysis) and 4 cases of acute rash have been reported. Eighteen
patients (12%) had developed at least a clear sign of a
paradoxal response (PR), 38 (25.3%) had a partial improvement
in their symptoms and 94 (62.7%) responded very well to
treatment. All PR patients underwent additional treatment
with corticosteroids. An improvement was noted in 15
patients at the end of treatment and 3 have kept enlarged
or abnormal ADP.
The majority of patients (53%) improved at the end of TB
treatment (regression in the size of ADP and improvement
of general health condition with no signs suggesting active
TB infection). Approximately 10% of patients have kept their
enlarged ADP, and 3 were considered treatment failure
(persistence of positive direct examination after treatment
completion). Five patients died after or during their treat-
ments: 1 patient following TB complications, 1 case of severe
hepatitis, and 3 others from associated diseases.
Discussion
Demography, epidemiology and risk factors
TBLA progresses rapidly compared with other forms in Tunisia
in recent years; the estimated incidence increased from 2.3
cases per 100,000 inhabitants in 1995 to 5.8 cases in 2010 [4].
This phenomenon is also observed globally: Menon et al.
reported a net increase from 0 to 19 cases of TBLA, while hav-
ing a global decrease in the TB cases count [14]. The subjects
are rather young and come from high TB prevalence countries
(Southeast Asia) [7,13,14]. Other reports confirm high rates
among immigrants from these regions in developed countries
[13,14]. This study has identified a relatively young age (20–
30 years) in line with what is reported in the literature in devel-
oping countries [6,7,10,14]. Female to male ratio varies from
1.1:1 [14] to 1.8:1 [7,8], or even 2.1:1 [15]. Fontanilla et al. relate
a world average of 1.4:1 [16]. The ratio in the present study of
1.78:1 is similar to that found in these countries. Purohit
et al. and Oloya et al. explained this dominance by unfavorable
socio-economic conditions and certain cultural and social
practices and habits in these countries [17].
Consumption of milk and raw milk products appears to
play a key role in the transmission of mycobacteria. M. bovis
has long been known for its ability to spread to the digestive
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believed to be the main cause behind TBLA [18]. Preventive
measures to limit bovine TBLA in developed countries during
the past century have effectively decreased human infection
with M. bovis, 92–98% of the isolates belong to the species
M. tuberculosis [16,18,19]. In Europe, M. bovis is no longer
responsible for EPTB, against 36.4% in Ethiopia, a country with
a strong cultural tradition of raw milk consumption [19].
Cheese consumption found in Hispanic communities in the
United States has had the effect of raising the ratio of M.
bovis/M. tuberculosis from 2% to more than 29.4% [18]. In this
series, milk consumption affects 1/3 of the study population,
and although microbiological identification concerned only 5
strains, 3 of them resulted in M. bovis, which suggests a pos-
sible wide endemicity. According to the latest report of basic
healthcare management administration, M. bovis is involved
in 30–50% of all documented cases of TBLA.
HIV is the most discussed risk factor in the past two dec-
ades in TB literature [1,3,12]. Over 50% of observed forms of
TB in seropositive patients are typical EPTB [12]. This can be
explained by the specific deficit in CD4 + T lymphocytes and
therefore the absence of specific macrophage activation
against TB antigens [12]. The INF-c response is decreased dur-
ing HIV infection. The immune response and tissue hypersen-
sitivity are absent or greatly decreased [20], therefore, the
clinical manifestation of TBLA is radically different [21]. No
cases of HIV/TBLA co-infection has been retained in this ser-
ies, which is in agreement with other studies conducted in
countries with low HIV prevalence [22].
Congenital immunodeficiency concerned 2 patients in this
series, the first having a quantitative deficiency of receptors
for IL-12, essential to the generation of an anti-microbial-
based response specifically involving activation of PNN and
macrophages [20]. This patient developed an opportunistic
disseminated infection following vaccination with BCG at
birth. The lymph node involvement is described in the litera-
ture for this type of hereditary disease [23]. Chronic granulo-
matous disease was found in the second patient, and is also
an etiology of disseminated TB and should be considered in
any case of unexplained massive TBLA in children following
vaccination with BCG [23].
Two studies reported a statistically significant and inver-
sely proportional relationship between the occurrence of
TBLA and diabetes mellitus [13,24]. However, no explanation
to this date has been formulated.
Clinical and paraclinical
TBLA is characterized by an impaired clinical presentation
[13]. Its diagnosis is made difficult by the subacute and fickle
nature of general signs [7,8,12,16]. The classic TB signs are
less frequent in TBLA than in PTB [7]. For example, the rates
vary considerably between 19% and 40% for fever [16]. In this
study, 44.7% of these patients showed at least one sign;
weight loss and prolonged fever were observed in 32% and
21% of cases, respectively. Wahid et al. report weight loss
and prolonged fever rates in 24.7% and 34.6% of cases, respec-
tively [25]. Khan reports in his study in Qatar up to 85% of
patients with night sweats, 77% of patients with anorexia,
62% of patients with severe weight loss and 40% with cough[26]. Biadglegne et al. provide that the different frequencies
between the studies/regions have a relationship with the bac-
terial load during contamination. These signs prove to be
almost always present in immunodeficient patients [19].
All studies, including the present study, agree on the fact
that the majority of ADP is one-sided and localized in the
head and neck region. Sharma et al. reported in a meta-
analysis that 2/3 of TBLA are strictly cervical [8]. Fontanilla
et al. report an average of between 45% and 70% based on 4
trials with 85% unilateral ADP between 1 and 3 cm [16]. The
deep sites (mesenteric and mediastinal) are the least
observed in practice and compromise immune impaired
patients. However, the limited number of confirmed cases,
coupled with a low sample survey and a real difficulty in spot-
ting deep ADP in practical routine checks does not reflect the
true extent of the involvement of other nodal sites [12]. In
studies that included imaging and CT scans as a means of
diagnosis, the rate of mediastinal ADP was more importantly
up to 26.7% [15]. Spontaneous fistula to the skin was noted in
18% of cases. This result is significantly greater than the aver-
age of 4–11% reported in the literature [16].
Pathological and microbiological diagnosis
Histology is today the most used medium in the diagnosis of
TBLA, not only in this series, but also in everyday practice
[7,9,10,13,27]. However, the WHO considers the identification
of the bacteria by direct examination or culture methods as
the only guarantee for positive TB infection [1]. FNA has the
advantage of being much more convenient to clinicians,
cheaper and less burdensome for the patients, and is by far
the ideal choice in developing countries with a high preva-
lence of TB [7,15,16]. Compared with other cases, biopsy was
much used in this study. [15] The pathological pattern for
TB infection in biopsy samples is the rearrangement of the
normal structure of the lymph node tissue into tuberculous
granulomas, with or without caseous necrosis and
Langerhans-type cells [7]. The main characteristic sought in
the FNAC is the presence of epithelioid cells in clusters with
or without necrotic material [7]. The sensitivity of the patho-
logical examination differs between samples, operating pro-
tocols and nature of required materials [13]. It has been
noted in this series there is an improved sensitivity for biopsy
against the FNA (94.2% against 62.5%), which is consistent
with several other studies. The literature reports widely vary-
ing rates for FNA, ranging from 9% [27] up to 90% [13], with
most studies between 55% and 85% [13,16]. The sensitivity
of biopsy is significantly higher with rates ranging from 84%
to 100% [9,13,16,27].
Direct examination by Ziehl Neelsen staining should be
routinely used for each sample and a culture made if possible,
or in case of strong suspicion of TB. In this study, the majority
of the patients (69%) have not been subject to any microbio-
logical screening. Marrakchi et al. noted 37 microbiological
analyses among 50 cases of TBLA and 9 biopsy cultures of
32 samples [9]. The sensitivity varies considerably from one
study to another. This result is within the limits of the overall
average. The sensitivity of the culture, either from biopsy
sampling or FNA, is greater than that reported by Marrakchi
et al. (7/26 against 1/9), whether the direct examination was
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[9].
Overall, the sensitivity of microbiological methods is con-
sidered mediocre and disparate. Bayazit et al. estimated the
sensitivity of culture between 10% and 69% [28]. The sensitiv-
ity of FNA is between 15% and 40% in the meta-analysis of
Mazza-Stalder et al. [29], and 17–82% with Polesky et al. [13].
Few studies have addressed the diagnostic approach using
MGIT. The present study found 2 positive cultures from 14
cases (14.9%). Polesky et al. have found 25 positive cultures
out of 111 cases (23%) [13]. In a comparative study using
MGIT/ LJ, Rodrigues et al. have found a sensitivity of 26%
(n = 1451) against only 10% for culture on LJ [30]. MGIT med-
ium allowed for a gain in terms of sensitivity and detection
limit.
Treatment and evolution
The American Thoracic Society (ATS), Centers for Disease
Control and Prevention (CDC) and Infectious Diseases
Society of America (IDSA) all recommend treating TBLA for
a nominal duration of 6 months: 2 months of daily quadruple
anti-tuberculous drugs and 4 months of daily bi-therapy or 3
times a week, with at least 2 major anti-TB drugs prescribed
during the course of treatment [16,31]. There is no clear con-
sensus on a global scale for the treatment of TBLA, including
the duration of treatment which varies widely in this popula-
tion (2–32 months), but is in general consistent with the cur-
rent practices in the field. The majority of these patients
were treated for an intended period of 9 months, which is
consistent with the French trend of Lanoix et al. [11] and
Clevenberg et al. [22]. Polesky et al. report an average of
7.2 months and a median at 6 months [13]. Using a treatment
period of 6 months has not had a significant impact on the
relapse rate, which authors put roughly to 3.3% for 6 months
and 2.7% for 9 months [28]. Abba et al. prescribed a 9-month
regimen in case of non-improved, new or worsening of ADP
[32]. Geldmacher et al. prescribed up to 12 months for more
than 40% of their study population [15].
Paradoxical reaction is one of the most spectacular phe-
nomena found in the treatment of TB, defined by the deterio-
ration of the general condition during the course of
treatment. It is rare in the case of a pure PTB (<3%) [33], and
is 20–30% for the TBLA [34]. The present study reported a
lower number (25.3%). Risk factors for the occurrence of PR
according to Cho et al. are: a young age, male gender and a
mobile inflammatory lymph node appearance (n = 235,
p < 0.01) [35]. Gert et al. point out the peripheral ADP and ane-
mia (n = 76; p < 0.05) [33]. The physiology of PR is not yet clear
and a precise definition has not been the subject of consen-
sus. TBLA is not a life-threatening illness or requiring urgent
care [8,16]. The relapse rate is low with a well-led regimen;
this study shows a single case of relapse during the study per-
iod and 5 out of 181 patients have a history of TBLA. Polesky
et al. noted a higher rate at 9%, including one case of relapse
after 8 years of primary infection [13]. The persistence of ADP
after the end of treatment without other clinical symptoms
was observed in 10% of cases. It is not an actual failure and
is far from trivial; Abba et al. noted that 34% of patients had
residual ADP without other clinical signs [36].Conclusion
TBLA remains a topical disease. Today, its diagnosis and
management are problematic and may in some contexts
be overlooked despite a growing incidence worldwide in
recent years. Disease control should be strengthened in this
country.Conflict of interest
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